Diabetes Care, Vol 20, Issue 1 71-73, Copyright © 1997 by American Diabetes Association

ARTICLES

Severe antibody-mediated human insulin resistance: successful treatment with the insulin analog lispro. A case report

JT Lahtela, M Knip, R Paul, J Antonen and J Salmi
Department of Medicine, University of Tampere, Finland. kljola@uta.fi

OBJECTIVE: To evaluate the efficacy of the insulin analog lispro (Lys B28, Pro B29) in severe insulin resistance caused by human insulin antibodies. CASE: A 27-year-old man with a history of diabetes treated with human insulin for 3 years developed severe immunological insulin resistance caused by human insulin antibodies. Throughout follow-up (12 months) the insulin analog lispro was administered with an infusion pump as the only insulin therapy. The insulin dose decreased from an average of 300 U/day to 58 U/day, HbA1c decreased from 12.6 to 7.4%, and human insulin antibodies decreased from 8,057 to 1,860 nU/ml. Hypoglycemic episodes during early morning disappeared. CONCLUSIONS: The insulin analog lispro might be suitable for the treatment of diabetic patients with substantially increased insulin antibody levels Apparently, the structural difference between the lispro and human insulin molecules prevented lispro from binding to the human insulin antibodies in this patient and consequently was nonimmunogenic.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				K. Stoneking Initiating basal insulin therapy in patients with type 2 diabetes mellitus Am. J. Health Syst. Pharm., March 1, 2005; 62(5): 510 - 518. [Abstract] [Full Text] [PDF]

				P. Gillard, Z. Ling, M. Lannoo, B. Maes, G. Maleux, D. Pipeleers, B. Keymeulen, and C. Mathieu {beta}-Cell Transplantation Restores Metabolic Control and Quality of Life in a Patient With Subcutaneous Insulin Resistance Diabetes Care, September 1, 2004; 27(9): 2243 - 2244. [Full Text] [PDF]

				S. E. Fineberg, J. Huang, R. Brunelle, K. S. Gulliya, and J. H. Anderson Jr Effect of Long-Term Exposure to Insulin Lispro on the Induction of Antibody Response in Patients With Type 1 or Type 2 Diabetes Diabetes Care, January 1, 2003; 26(1): 89 - 96. [Abstract] [Full Text] [PDF]

				Z. Vajo, J. Fawcett, and W. C. Duckworth Recombinant DNA Technology in the Treatment of Diabetes: Insulin Analogs Endocr. Rev., October 1, 2001; 22(5): 706 - 717. [Abstract] [Full Text] [PDF]

				M. E. Griffin, A. Feder, and W. V. Tamborlane Lipoatrophy Associated With Lispro Insulin in Insulin Pump Therapy: An old complication, a new cause? Diabetes Care, January 1, 2001; 24(1): 174 - 174. [Full Text]

				Z. Vajo and W. C. Duckworth Genetically Engineered Insulin Analogs: Diabetes in the New Millenium Pharmacol. Rev., March 1, 2000; 52(1): 1 - 10. [Abstract] [Full Text] [PDF]

				J P H Shield and J D Baum Advances in childhood onset diabetes Arch. Dis. Child., April 1, 1998; 78(4): 391 - 394. [Full Text]

				F. Holleman and J. B.L. Hoekstra Insulin Lispro N. Engl. J. Med., July 17, 1997; 337(3): 176 - 183. [Full Text] [PDF]